EBITDA: Income before interest, taxes, depreciation and amortization.
Bone Biologics Corp. (BBLG) had EBITDA of $-0.81M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-0.77M |
|
-- |
|
-- |
|
$0.81M |
|
$-0.81M |
|
$0.04M |
|
$-0.77M |
|
$-0.77M |
|
$-0.77M |
|
$-0.77M |
|
$-0.77M |
|
$-0.77M |
|
$-0.81M |
|
|
EBITDA |
$-0.81M |
1.80M |
|
1.80M |
|
$-0.43 |
|
$-0.43 |
|
| Balance Sheet Financials | |
$4.98M |
|
-- |
|
-- |
|
$4.98M |
|
$0.31M |
|
-- |
|
-- |
|
$0.31M |
|
$4.67M |
|
$4.67M |
|
$4.67M |
|
1.79M |
|
| Cash Flow Statement Financials | |
$-0.80M |
|
-- |
|
-- |
|
$5.33M |
|
$4.53M |
|
$-0.80M |
|
$0.02M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
16.09 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-0.80M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-16.40% |
|
-16.40% |
|
-15.38% |
|
-16.40% |
|
$2.60 |
|
$-0.45 |
|
$-0.45 |
|